Table 1: US sales and growth of drug classes in the antidyslipidemic market, 2007 9
Table 2: Japan sales and growth of drug classes in the antidyslipidemic market, 2007 22
Table 3: An example of the savings to be realized by using generic drugs in Japan, 2006 31
Table 4: France sales and growth of drug classes in the antidyslipidemic market, 2007 35
Table 5: Germany sales and growth of drug classes in the antidyslipidemic market, 2007 45
Table 6: Italy sales and growth of drug classes in the antidyslipidemic market, 2007 53
Table 7: Spain sales and growth of drug classes in the antidyslipidemic market, 2007 63
Table 8: UK sales and growth of drug classes in the antidyslipidemic market, 2007 71
Table 9: The 10 clinical areas of the Quality Outcome Framework, as outlined in the GMS contract, 2005 76
Table 10: Formulary status in the US for leading brands in dyslipidemia, 2007 89
Table 11: Lipitor: key facts, 2008 91
Table 12: Sales forecast ($m) for Lipitor in the seven major markets ($m), 2007-2017 93
Table 13: Impacting factors on Lipitor revenues, 2008-2017 95
Table 14: Vytorin: key facts, 2008 98
Table 15: Sales forecast for Vytorin in the seven major markets ($m), 2008-2017 100
Table 16: Impacting factors on Vytorin, revenues, 2007-2017 102
Table 17: Crestor: key facts, 2008 104
Table 18: Sales forecast for Crestor in the seven major markets ($m), 2007-2017 105
Table 19: Impacting factors on Crestor revenues, 2008-2017 108
Table 20: Summary of pipeline antidyslipidemic agents that are likely to launch with the forecast period, 2008-2017 111
Table 21: Sales forecast ($m) for TriLipix for dyslipidemia in the 7MM, 2007-2017 115
Table 22: Impacting factors on the revenues of TriLipix, 2007-2017 115
Table 23: Leading 10 companies in the seven major markets dyslipidemia market, 2007-2017 128
Table 24: Strategic importance of antidyslipidemic drugs to leading companies' portfolios, 2007 129
Table 25: Summary of statin-containing SPCs that are likely to launch within the forecast period, 2007-2017 154
Table 26: Phase II trial results for the atorvastatin + torcetrapib combination 167
Table 27: Mean percentage increase in HDL-C 168
Table 28: Mean percentage decrease in LDL-C 168
Table 29: Patient discontinuation results 169
Table 30: Summary of torcetrapib's late-stage clinical development, 2006 170
Table 31: Datamonitor's launch dates for antidyslipidemics in the 5EU and US, 2008-2017 207
Table 32: Patent expiry dates for the approved antidyslipidemics in the seven major markets, 2008-2017 208
Figure 1: Annual US sales ($m)of the antidyslipidemic drug classes, 2004-07 10
Figure 2: Performance of the key antidyslipidemic therapies in the US ($m), 2006-07 11
Figure 3: Market share of antidyslipidemic drugs in the US, 2007 versus 2017 12
Figure 4: New US Patent and Trademark Office (PTO) rules are unfavorable for Pharma and biotech 21
Figure 5: Annual Japan sales of the antidyslipidemic drug classes, 2004-07 23
Figure 6: Performance of the key antidyslipidemic therapies in Japan ($m), 2006-07 24
Figure 7: Market share of antidyslipidemic drugs in Japan, 2007 versus 2017 25
Figure 8: Annual France sales of the antidyslipidemic drug classes, 2004-07 36
Figure 9: Performance of the key antidyslipidemic therapies in France ($m), 2006-07 37
Figure 10: Market share of antidyslipidemic drugs in France, 2007 versus 2017 38
Figure 11: Annual Germany sales of the antidyslipidemic drug classes, 2004-07 46
Figure 12: Performance of the key antidyslipidemic therapies in Germany ($m), 2006-07 47
Figure 13: Market share of antidyslipidemic drugs in Germany, 2007 versus 2017 48
Figure 14: Annual Italy sales of the antidyslipidemic drug classes, 2004-07 54
Figure 15: Performance of the key antidyslipidemic therapies in Italy ($m), 2006-07 55
Figure 16: Market share of antidyslipidemic drugs in Italy, 2007 versus 2017 56
Figure 17: Annual Spain sales of the antidyslipidemic drug classes, 2004-07 64
Figure 18: Performance of the key antidyslipidemic therapies in Spain ($m), 2006-07 65
Figure 19: Market share of antidyslipidemic drugs in Spain, 2007 versus 2017 66
Figure 20: Annual UK sales of the antidyslipidemic drug classes, 2004-07 72
Figure 21: Performance of the key antidyslipidemic therapies in the UK ($m), 2006-07 73
Figure 22: Market share of antidyslipidemic drugs in the UK, 2007 vs. 2017 74
Figure 23: Rest of World versus seven major market sales in the antidyslipidemic market ($ billion and %), 2007 81
Figure 24: Global antidyslipidemic sales growth by region (%), 2004-07 82
Figure 25: Top 10 cardiovascular brands in the seven major markets by sales, 2004-2017 84
Figure 26: Sales of top 10 brands in the seven major markets, 2004-17 85
Figure 27: Sales forecast for Lipitor in the seven major markets ($ billion), 2007-2017 94
Figure 28: The relationship between the pricing advantage and the market share of Vytorin, 2007 96
Figure 29: Sales forecast for Vytorin in the seven major markets ($ billion), 2008-2017 101
Figure 30: Sales forecast for Crestor in the seven major markets ($ billion), 2008-2017 107
Figure 31: Leading 4 companies as proportion of the whole market, 2007 versus 2017 128
Figure 32: Forecasted sales of Zetia, three scenarios, $m 160
Figure 33: Forecasted sales of Vytorin, three scenarios, $m 161
Figure 34: HDL-C metabolism and the role of CETP 163
Figure 35: HDL-C levels in male and female residents of the USA 164
Figure 36: Forecast sales of dalcetrapib across the seven major markets - three scenarios ($m), 2008-2017 183
Figure 37: Forecast sales of anacetrapib across the seven major markets - three scenarios ($m), 2008-2017 184
[Tabellenverzeichnis ausblenden]
